Alkylthioglycerol prodrugs of foscarnet: Synthesis, oral bioavailability and structure-activity studies in human cytomegalovirus-, herpes simplex virus type 1- and human immunodeficiency virus type 1-infected cells

Antiviral Chemistry and Chemotherapy

Volumn 9, Issue 1, 1998, Pages 33-40

  Beadle, J R ^a,b   Kini, G D ^a,b   Aldern, K A ^a   Gardner, M F ^a   Wright, K N ^a   Richman, D D ^a,b   Hostetler, K Y ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; Ether lipids; Herpes simplex virus type 1; Human immunodeficiency virus; Phospholipid ethers; Prodrugs; Thioether lipids

Indexed keywords

ETHER LIPID; ETHER PHOSPHOLIPID; FOSCARNET DERIVATIVE; PRODRUG; THIOETHER PHOSPHOLIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG SYNTHESIS; HERPES SIMPLEX VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0031965310     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029800900104     Document Type: Article

References (19)

1. Balfour HHJ, Fletcher CV, Erice A, Henry WK, Acosta EP, Smith SA, Marlene AH, Boivin G, Shepp DH, Crumpacker CS, Eaton CA & Martin-Munley SS (1996) Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. Antimicrobial Agents & Chemotherapy 40:2721-2726.
2. Charvet A-S, Camplo M, Faury P, Graciet JC, Mourier N, Chermann J-C & Kraus J-L (1994) Inhibition of human immunodeficiency virus type 1 replication by phosphonoformate -and phosphonoacetate-2′,3′-dideoxy-3′-thiacytidine conjugates. Journal of Medicinal Chemistry 37:2216-2223.
3. Chrisp P & Clissold SP (1991) Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104-129.
4. Drusano GL, Aweeka F, Gambertglio J, Jacobson M, Polis M, Lane HC, Eaton C & Martin-Munley S (1996) Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV-positive patients. AIDS 10:1113-1119.
5. Freeman WR (1996) New developments in the treatment of CMV retinitis. Ophthalmology 103:999-1000.
6. Hong CI, Nechaev A, Kirisits AJ, Vig R, West CR, Manouilov KK & Chu CK (1996) Nucleoside conjugates. 15. Synthesis and biological activity of anti-HIV nucleoside conjugates of ether and thioether phospholipids. Journal of Medicinal Chemistry 39:1771-1777.
7. Hostetler KY, Kini GD, Beadle JR, Aldern KA, Gardner MF, Border R, Kumar R, Barshak L, Sridhar CN, Wheeler CJ & Richman DD (1996) Lipid prodrugs of phosphonoacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 and HCMV-infected cells, in vitro. Antiviral Research 31:59-67.
8. Jacobson MA (1996) Current management of cytomegalovirus retinitis in AIDS: update on ganciclovir and foscarnet for CMV infections. In Antiviral Chemotherapy 4, pp. 85-92. Edited by J Mills, PA Volberding & L Corey. New York: Plenum Press.
9. Jung ME & Shaw TJ (1980) Total synthesis of (R)-glycerol acetonide and the antiepilectic and hypotensive drug (-)-γ-amino-β-hydroxybutyric acid (GABOB): use of vitamin C as a chiral starting material. Journal of the American Chemical Society 102:6304-6311.
10. Kaiser L, Perrin L, Hirschel B, Furrer H, Overbeck JV, Olmari M & Yerly S (1995) Foscarnet decreases human immunodeficiency virus RNA. Journal of Infectious Diseases 172:225-227.
11. Kini GD, Beadle JR, Xie H, Aldern KA, Richman DD & Hostetler KY (1997a) Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV. Antiviral Research 36:43-53.
12. Kini GD, Hostetler SE, Beadle JR & Aldern KA (1997b) Synthesis and antiviral activity of 1-O-octadecyl-2-0-alkyl-sn-glycero-3-foscarnet conjugates in human cytomegalovirus-infected cells. Antiviral Research 36:115-124.
13. Kucera LS, AIyer N, Leake E, Raben A, Modest EJ, Daniel LW & Piantadosi C (1990) Novel membrane-interactive ether lipid analogues that inhibit infectious HIV-1 production and induce defective virus formation. AIDS Research and Human Retroviruses 6:491-501.
14. Larder BA, Chesbro B & Richman DD (1990) Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined using a quantitative plaque reduction assay. Antimicrobial Agents & Chemotherapy 34:436-441.
15. Öberg B (1989) Antiviral effects of phosphonoformate (PFA, foscarnet sodium). Pharmacology & Therapeutics 40:213-285.
16. Pleskoff O, Treboute C, Brelot A, Heveker N, Semen M & Alizon M (1997) Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. Science 276:1874-1878.
17. Polis MA, deSmet MD & Baird BF (1993) Increased survival of a cohort of patients with AIDS and CMV retinitis who received sodium phosphonoformate (foscarnet). American Journal of Medicine 94:175-180.
18. Smith NA, Wood C, Asboe D & Bingham JS (1997) Topical foscarnet for acyclovir-resistant mucocutaneous herpes infections in AIDS. AIDS 11:254-255.
19. Snyder F, Piantadosi C & Wood R (1969) Metabolism of glyceryl thioethers. Proceedings of the Society for Experimental Biology and Medicine 130:1170-1174.